ReviewACS omega2025
Point-of-Care Nucleic Acid Detection: From Molecular Design to Clinical Reality.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Special Issue "Advances in Diagnostics: Applications of Nucleic Acids and Their Analogs".International journal of molecular sciences · 2026Article
- Integration of Nanotechnology with ctDNA: New Advances for Monitoring Neoadjuvant Chemotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Point-of-Care (PoC) diagnostics are transforming healthcare by enabling rapid and accessible disease detection right at the patient's bedside. This comprehensive review examines recent advances in nucleic acid (NA)-based PoC testing, revealing how these technologies are revolutionizing molecular diagnostics. Here, we critically analyze the three key components of NA-based PoC development: (i) probe design strategies, (ii) immobilization techniques, and (iii) detection methodologies. Our analysis uncovers the complex relationship between probe density, hybridization conditions, and detection sensitivity, challenging the conventional trial-and-error approaches currently dominating the field. The review introduces a novel classification of detection methods based on equipment requirements, offering valuable insights for developing truly accessible diagnostic solutions. Notably, we highlight that colorimetric and electrochemical detection methods show superior potential in meeting the REASSURED criteria (Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, Real-time connectivity, Ease of specimen collection, and Deliverable to end-users). These criteria are essential for global healthcare implementation. Despite major advances, significant gaps remain between laboratory innovations and practical, affordable diagnostic products. We suggest that prioritizing equipment-free detection methods and enhancing standardization could accelerate the translation of these PoC technologies into clinical practice. This review outlines a strategic roadmap for advancing NA-based PoC diagnostics, emphasizing the potential to transform healthcare delivery worldwide through accessible, rapid, and reliable molecular testing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.